Lifetech Sci (01302) saw its shares surge more than 4% in late trading. As of the time of writing, the stock was up 4.07%, trading at HK$1.79, with a turnover of HK$37.7646 million. On the news front, on January 9th, the Concave Supra integrated aortic arch triple-branch reconstruction system, jointly developed by Professor Shu Chang from Fuwai Hospital of the Chinese Academy of Medical Sciences, National Center for Cardiovascular Diseases, and Lifetech Sci, was approved by the National Medical Products Administration to enter the Innovative Medical Device Special Review Process, also known as the national innovation "green channel". Reportedly, the CS stent system is Lifetech's 17th self-developed innovative product approved for entry into the national innovation "green channel". Public information indicates that this product is suitable for the minimally invasive treatment of complex aortic arch aneurysms and penetrating ulcers, representing the world's first integrated aortic arch triple-branch reconstruction solution that eliminates cerebral ischemia. This product, together with the innovative product matrix for chimney technology in aortic arch branch reconstruction, the innovative product matrix for in-situ fenestration technology in aortic arch branch reconstruction, and the SureCham single-branch stent system, will collectively form Lifetech's unique comprehensive endovascular treatment solution for aortic arch diseases.